DrugPatentWatch Database Preview
Baricitinib - Generic Drug Details
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What are the generic sources for baricitinib and what is the scope of patent protection?
Baricitinib
is the generic ingredient in one branded drug marketed by Eli Lilly And Co and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Baricitinib has fifty-four patent family members in forty-two countries.
One supplier is listed for this compound.
Summary for baricitinib
| International Patents: | 54 |
| US Patents: | 2 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 82 |
| Clinical Trials: | 52 |
| Patent Applications: | 71 |
| DailyMed Link: | baricitinib at DailyMed |
Recent Clinical Trials for baricitinib
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Washington University School of Medicine | Phase 1 |
| University Hospital, Brest | Phase 2 |
| Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 2 |
Pharmacology for baricitinib
| Drug Class | Janus Kinase Inhibitor |
| Mechanism of Action | Janus Kinase Inhibitors |
Synonyms for baricitinib
| (1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)ethanenitrile |
| {1-(ethylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azetidin-3-yl}acetonitrile |
| 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile |
| 1187594-09-7 |
| 2-(3-(4-(3H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile |
| 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile |
| 2-[1-ETHYLSULFONYL-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PYRAZOL-1-YL]AZETIDIN-3-YL]ACETONITRILE |
| 3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)- |
| 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- |
| 3JW |
| AB0035958 |
| ABP001023 |
| AC-27404 |
| AJ-121247 |
| AK143352 |
| AKOS022186127 |
| AKOS025401933 |
| AM81232 |
| AMMD00005 |
| AOB87724 |
| AX8261519 |
| Baricitinib (INCB28050 LY3009104) |
| Baricitinib (JAN/USAN/INN) |
| Baricitinib (LY3009104, INCB028050) |
| Baricitinib (LY3009104) |
| Baricitinib [USAN:INN] |
| baricitinib-ly3009104 |
| BC600315 |
| BCP04686 |
| BCP0726000031 |
| BCP9000380 |
| BDBM50021656 |
| C16H17N7O2S |
| CHEBI:95341 |
| CHEMBL2105759 |
| CS-0724 |
| D10308 |
| DB11817 |
| DS-7641 |
| DTXSID30152228 |
| EX-A413 |
| GTPL7792 |
| HMS3651L17 |
| HY-15315 |
| INCB 028050 |
| INCB 28050 |
| INCB-028050 |
| INCB-028050|||LY-3009104|||2-[1-Ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile |
| INCB028050 |
| ISP4442I3Y |
| J-503551 |
| KS-0000044L |
| LY 3009104 |
| LY-3009104 |
| LY3009104 |
| MFCD21608464 |
| MLS006011247 |
| NCGC00345839-01 |
| NCGC00345839-14 |
| olumiant |
| Olumiant (TN) |
| PB27275 |
| QCR-197 |
| RL00725 |
| S-7686 |
| s2851 |
| SB10845 |
| SC-94301 |
| SCHEMBL871150 |
| SMR004703006 |
| SW220096-1 |
| UNII-ISP4442I3Y |
| XUZMWHLSFXCVMG-UHFFFAOYSA-N |
| Y0439 |
| ZINC73069247 |
US Patents and Regulatory Information for baricitinib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-001 | May 31, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-001 | May 31, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-001 | May 31, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for baricitinib
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Poland | 2288610 | Start Trial |
| Chile | 2009000576 | Start Trial |
| Hong Kong | 1149005 | Start Trial |
| Slovenia | 2288610 | Start Trial |
| South Korea | 20100121657 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for baricitinib
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2288610 | 1790035-8 | Sweden | Start Trial | PRODUCT NAME: BARICITINIB; REG. NO/DATE: EU/1/16/1170 20170215 |
| 2288610 | PA2017023 | Lithuania | Start Trial | PRODUCT NAME: BARICITINIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/16/1170 20170213 |
| 2288610 | 2017C/025 | Belgium | Start Trial | PRODUCT NAME: OLUMIANT - BARICITINIB; AUTHORISATION NUMBER AND DATE: EU/1/16/1170 20170215 |
| 2288610 | CA 2017 00032 | Denmark | Start Trial | PRODUCT NAME: BARICITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1 /16/1170 20170215 |
| 2288610 | PA2017023,C2288610 | Lithuania | Start Trial | PRODUCT NAME: BARICITINIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/16/1170 20170213 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.